Repair of an intercalated long bone defect with a synthetic biodegradable bone-inducing implant.
Recombinant human bone morphogenetic protein (rhBMP)-2 in a block copolymer composed of poly-D,L-lactic acid with randomly inserted p-dioxanone and polyethylene glycol (PLA-DX-PEG) as a carrier and porous beta-tricalcium phosphate (beta-TCP) blocks were used to generate a new fully absorbable osteogenic biomaterial. The bone regenerability of the rhBMP-2/PLA-DX-PEG/beta-TCP composite was studied in a critical-sized rabbit bone defect model. In an initial study, a composite of PLA-DX-PEG (250 mg) and beta-TCP (300 mg) loaded with or without rhBMP2 (50 microg) was implanted into a 1.5 cm intercalated bone defect created in a rabbit femur. Defects were assessed by biweekly radiography until 8 weeks postoperatively. The bony union of the defect was recognized only in the BMP-loaded group. To obtain further data on biomechanical and remodeling properties, another BMP-loaded composites group was made and observed up to 24 weeks. All defects were completely repaired without residual traces of implants. Anatomical and mechanical properties of the repaired bone examined by histology, 3-dimensional CT (3D-CT) and mechanical testing were essentially equivalent to the nonoperated-on femur at 24 weeks. These experimental results indicate that fully absorbable rhBMP-2/PLA-DX-PEG/beta-TCP is a promising composite having osteogenicity efficient enough for repairing large bone defects.
Yoneda
Masahiro
M
Department of Orthopaedic Surgery, Osaka City University School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Terai
Hidetomi
H
Imai
Yuuki
Y
Okada
Takao
T
Nozaki
Kazutoshi
K
Inoue
Hikaru
H
Miyamoto
Shimpei
S
Takaoka
Kunio
K
D020341:Absorbable Implants; D015502:Absorptiometry, Photon; D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology; D001696:Biomechanical Phenomena; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D002146:Bony Callus / Q000254:growth & development; D002130:Calcium Phosphates / Q000737:chemistry; D005264:Femoral Fractures / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D005269:Femur / Q000473:pathology; D017102:Fracture Healing / Q000187:drug effects*; D048091:Guided Tissue Regeneration / Q000379:methods*; D006801:Humans; D007773:Lactates / Q000737:chemistry; D010012:Osteogenesis / Q000187:drug effects; D016687:Polydioxanone / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D011817:Rabbits; D011994:Recombinant Proteins / Q000494:pharmacology; D036542:Tomography, Spiral Computed; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D007773:Lactates; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C485817:beta-tricalcium phosphate; C088513:poly(lactic acid-ethylene glycol); C499469:recombinant human bone morphogenetic protein-2; D016687:Polydioxanone; D011092:Polyethylene Glycols